Fujifilm ramps up Avigan production as Japanese government stockpiles potential COVID-19 therapy
Japanese drugmaker plans to meet 100,000 treatment course target by July
Japanese pharma manufacturer Fujifilm is ramping up production of its influenza antiviral Avigan (favipiravir) as the Japanese government plans to stockpile the drug as a potential treatment for patients with COVID-19.
The company said it expects to progressively increase Avigan production up to 100,000 treatment courses by July 2020, around two and a half times more than at the beginning of March, when it began its current production run. It then intends to further accelerate production to 300,000 treatment courses by September 2020.
The Japanese government plans to stockpile 2 million treatment courses of Avigan, as part of its emergency economic package announced on April 7.
Fujifilm said that to boost supply, it is expanding capacity at its Wako Pure Chemical Co. facility for production of pharmaceutical intermediates used to manufacture Avigan.
“In addition, Fujifilm has established strategic partnerships with domestic and overseas companies for various manufacturing processes to source raw materials and pharmaceutical substances,” the company said in a statement.
According to Japanese Association for Infectious Diseases guidelines, favipiravir tablets should be administered as a treatment for COVID-19 for 14 days, including two 1800 mg loading doses on the first day followed by two 1,000 mg maintenance doses on days two to 14.
Avigan is only approved in Japan as an influenza antiviral, but it is currently going through phase II clinical trials to assess its effectiveness as a COVID-19 treatment. The drug selectively inhibit viral RNA polymerase necessary for influenza virus replication and it is this mechanism of action that scientists believe may have an antiviral effect on the SARS-Cov-2 coronavirus, because like influenza viruses, coronaviruses are single-stranded RNA viruses that also depend on viral RNA polymerase.
While Avigan is not approved for use in any overseas markets, last week Fujifilm also announced the start of a phase II clinical trial in the US to evaluate its safety and efficacy in treating COVID-19.
The US trial will enrol approximately 50 patients with COVID-19, in collaboration with Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance